Financial Shenanigans

Financial Shenanigans

Anthem reports clean cash conversion over the cycle (3-year CFO/Net Income of 0.99x), but the picture is uglier inside individual years and weaker once governance is factored in. The two largest concerns are not on the income statement: a roughly one-sixth-of-revenue customer routed through an intermediary affiliated with a Selling Shareholder that the company has chosen to treat as non-related-party, and a 2.5-year-old ramp of intercompany loans to a loss-making wholly-owned subsidiary that consolidation hides. Working-capital intensity (cash conversion cycle 124–202 days, three blow-out years out of seven) and an unusually loud FY26 "other income" line round out a Watch-grade profile. The single fact that would lower the grade further is a full statutory-auditor change to Big Four with a clean Year-1 opinion; the fact that would raise it is post-IPO related-party expansion with DavosPharma or Anthem Bio Pharma.

Shenanigans scorecard (13 categories)

Breeding Ground

The structural conditions around Anthem skew toward elevated shenanigans risk: family-owned, fresh-listed, mid-tier auditor, brand-new independent directors. None of this is misconduct, but it is the environment in which shenanigans more often happen than not.

The DavosPharma loophole is the single most important breeding-ground feature. Portsmouth LLC is a pre-IPO shareholder who sold in the OFS; its affiliate DavosPharma was Anthem's third-largest customer at 14.28% of FY2025 revenue (54.06% of all North America revenue), and the RHP states explicitly: "As DavosPharma is not a related party under the applicable accounting standards, and we enter into transactions with DavosPharma in the ordinary course of business on an arm's length basis, our transactions with DavosPharma are not subject to our audit committee's review or shareholders' approval." The economic relationship is captive — Anthem invoices DavosPharma, not the end customer — but the audit-committee firewall does not apply. This is the textbook "Type 2 affiliated customer" structure that historically requires monitoring as it can amplify other manipulations rather than constitute one by itself.

Earnings Quality

Reported earnings track operating reality more closely than not. The cleanest single fact is the 5-year CFO/NI of 0.93x (FY2022–FY2026); the dirtiest single fact is that the line is volatile inside that average, with two years (FY2023, FY2024) where reported profit ran well ahead of cash.

FY2024 is the cleanest place to see the problem: Net Income of ₹367 cr versus CFO of ₹140 cr (0.38x) and FCF of negative ₹156 cr. That single year carries an accrual ratio of +10.3%, meaning roughly a tenth of average total assets came from book accruals not yet supported by cash. FY2026 is the partial reversal — CFO of ₹844 cr against ₹592 cr of net income is 1.43x, with an accrual ratio of negative 8.1%. Both are signals that working capital is doing more of the heavy lifting than gross earnings power.

Other income — investment yield, foreign-exchange gains, and RoDTEP export incentives — was 32.3% of operating profit in FY2023 (₹139 cr on ₹431 cr) and has stepped up to 15.7% of operating profit in FY2026 (₹131 cr on ₹834 cr). The 9M FY2026 call disclosed for the first time that of the ₹105 cr "other income," about ₹41 cr is a newly carved-out "other operating income" (forex + RoDTEP) — a metric definition shift in real time that should be tracked. Stripping the non-operating element out of FY26 EBITDA pulls the headline margin from 41.5% to roughly 38–39%, which is the FY24 level rather than a structural step-up.

The FY2025 effective tax rate jump from 23% to 31% — with Q4 FY2025 a one-off 54% — is most plausibly the unwinding of EOU/SEZ deductions on the IPO restructuring path. It is a tailwind to FY2024 reported earnings that does not recur. There is no disclosure language to confirm or refute this; that absence is itself a yellow flag.

Cash Flow Quality

The honest summary: Anthem's CFO matches its net income on average, but that average is the product of two compensating distortions. FY2024 CFO was depressed by an inventory and receivables build; FY2026 CFO was lifted by the inventory unwind, by faster customer collections, and by paying suppliers significantly more slowly than historical practice.

The standout swings:

• Inventory days 167 → 56 between FY25 and FY26 — a 111-day collapse. Some of that is the destocking management referenced ("customers have rationalised stocks to lower safety stock"), but the magnitude is unusual and management did not attribute the inventory swing to a specific event in any of the three FY26 transcripts.
• Payable days 54 → 34 in the same year — Anthem is paying its suppliers faster, the opposite of the working-capital lifeline that usually flatters CFO. That is a small negative for cash but a quality signal for vendor relationships.
• Working capital days has expanded from 20 (FY20) to 207 (FY26). A CDMO business with longer end-customer credit terms (60–90 days disclosed) and longer manufacturing cycles will run more working capital, but a 10× expansion over six years is structural and means CFO does not equal NI cycle to cycle.

The working-capital wedge (red) became massively negative in FY2024 (a ₹309 cr drag), modestly negative in FY2025 (₹122 cr), and reversed to positive ₹118 cr in FY2026. That ₹430 cr swing from FY24 to FY26 explains essentially all of the headline CFO improvement.

The ₹329 cr Neoanthem loan in FY25 is 11.7% of Anthem's FY25 total assets. It funds Unit III construction and operating losses; the RHP discloses interest paid by the subsidiary to the parent offsets the subsidiary's interest expense. At the consolidated level this washes out — but at the standalone level, parent CFO is being supported by interest income from a wholly-owned loss-maker, while the subsidiary's CFO drag is borne by the consolidation. Management's frequently quoted "net cash" position (₹993 cr at Sep-2025, ₹785 cr at Jun-2025) presumably treats the intercompany loan asset as collectible at par; investors should mark it down by the probability it ever has to be written.

Metric Hygiene

Management's preferred metrics — EBITDA, EBITDA margin, PAT margin, "net cash," and "asset turnover" — are disclosed at a reasonable level of detail by Indian standards but include several definition choices that go in the company's favour.

The ESOP charge timing deserves a closer look. Management volunteered on the Q2 FY26 call that ₹36 cr of ESOP cost hit H1 FY25 (the first allotment year), ₹16 cr is spread across FY26 on a sliding scale, "and going forward, it's going to come down further." The 23% YoY EBITDA growth headlined in 9M FY26 is therefore mechanically helped by a ~₹20 cr swing in non-cash charges. Stripping the ESOP delta, underlying EBITDA growth in 9M FY26 is closer to 19% than 23%. Honest, but not what the call emphasises.

That ₹566 cr underlying CRDMO EBITDA on ₹1,513 cr revenue is a 37.4% margin — still excellent for a pharma services business, but ~4 percentage points below the headline. The forensic question is whether sell-side models are using ₹671 cr or ₹566 cr as the FY26 run-rate.

What to Underwrite Next

The five things to track between now and the FY2026 audit / FY2027 disclosures:

1. DavosPharma revenue concentration and contract terms. The trend is constructive (37.16% in FY23 → 22.75% in FY24 → 14.28% in FY25) as Anthem moves to direct customer contracts. If FY26 reverses that decline, or if Portsmouth LLC reappears as a customer-side party in any disclosure, the related-party loophole moves from yellow to red.
2. Neoanthem intercompany loan balance. ₹23 cr → ₹175 cr → ₹329 cr in three years. If FY26 brings another step-up materially above standalone CFO, or if the subsidiary remains loss-making into FY27, the consolidation is shielding parent-level economics that a standalone investor would not see.
3. Auditor. K.P. Rao & Co. is small for a ~₹44,000 cr market-cap listed company. A rotation to a Big Four firm (mandatory rotation under Indian rules every 10 years) would close one yellow flag; a re-appointment without rotation would not.
4. Other-income mix. The ₹41 cr "other operating income" carve-out introduced 9M FY26 is the disclosure to watch. If FY27 redefines it (RoDTEP withdrawal, hedging policy change, or recategorising into revenue from operations), the EBITDA-margin sequence becomes non-comparable.
5. CCC normalisation. A return of the cash conversion cycle to 140–150 days, with payable days back at 50+ and inventory days in the 80–100 range, would confirm FY26 was a normal cycle. A repeat of the 200+ day expansion would mean the CFO surprise was a one-time unwind, not a step-change.

The diligence call. Treat Anthem's accounting risk as a position-sizing limiter, not a thesis breaker. The mechanics are clean over the cycle and there is no evidence of revenue, expense, or reserve manipulation that would change the underwriting case. But the breeding ground — promoter-dominant board, mid-tier auditor, just-installed independents, OFS-only exit IPO, an economically-related customer worth one-sixth of revenue that is outside the related-party disclosure regime — is exactly the environment in which one or two of the small yellows can become large reds over a 24-month horizon. A reasonable analyst response is a 5–10% valuation haircut versus a peer with cleaner governance, plus an explicit position cap until the FY27 RPT disclosure clears or DavosPharma exposure shrinks below 5% of revenue.